John P. Shannon's most recent trade in Teradyne, Inc. was a trade of 4,460 Common Stock done . Disclosure was reported to the exchange on Feb. 4, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Teradyne | Shannon John Poulin | President, Semiconductor Test | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2026 | 4,460 | 17,235 (0%) | 0% | 0 | Common Stock | |
| Teradyne | Shannon John Poulin | President, Semiconductor Test | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2026 | 3,937 | 3,937 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2026 | 639,639 | 639,639 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2026 | 478,436 | 3,276,083 (12%) | 1% | 0 | Common Stock | |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.36 per share. | 30 Jan 2026 | 118,134 | 3,157,949 (11%) | 0% | 7.4 | 869,466 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.36 per share. | 30 Jan 2026 | 111,621 | 3,046,328 (11%) | 0% | 7.4 | 821,531 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.36 per share. | 30 Jan 2026 | 110,750 | 2,935,578 (10%) | 0% | 7.4 | 815,120 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.55 per share. | 05 Jan 2026 | 64,265 | 2,769,611 (10%) | 0% | 1.6 | 99,611 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2026 | 64,265 | 0 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.55 per share. | 05 Jan 2026 | 25,136 | 2,794,747 (10%) | 0% | 1.6 | 38,961 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2026 | 25,136 | 0 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 7.08 per share. | 05 Jan 2026 | 24,907 | 2,705,346 (9%) | 0% | 7.1 | 176,257 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2026 | 2,900 | 97,100 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.94 per share. | 05 Jan 2026 | 2,900 | 2,797,647 (10%) | 0% | 3.9 | 11,426 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 87,100 | 64,265 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.55 per share. | 13 Nov 2025 | 87,100 | 2,730,253 (10%) | 0% | 1.6 | 135,005 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 7.46 per share. | 13 Nov 2025 | 23,242 | 2,643,153 (9%) | 0% | 7.5 | 173,402 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 8,970 | 151,365 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.55 per share. | 13 Nov 2025 | 8,970 | 2,666,395 (9%) | 0% | 1.6 | 13,904 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.38 per share. | 01 Aug 2025 | 36,918 | 2,657,425 (9%) | 0% | 5.4 | 198,619 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 800,000 | 2,687,118 (9%) | 2% | 0 | Common Stock | |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 600,000 | 600,000 | - | - | Stock Appreciation Right | |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.56 per share. | 31 Jan 2025 | 110,750 | 1,997,868 (7%) | 0% | 3.6 | 394,270 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.56 per share. | 31 Jan 2025 | 110,750 | 1,887,118 (6%) | 0% | 3.6 | 394,270 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.61 per share. | 03 Jan 2025 | 39,443 | 2,108,618 (7%) | 0% | 3.6 | 142,389 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2022 | 300,000 | 300,000 | - | - | Stock Appreciation Right | |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2022 | 250,000 | 2,419,612 (8%) | 0% | 0 | Common Stock | |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.46 per share. | 29 Jan 2022 | 110,750 | 2,148,061 (7%) | 0% | 2.5 | 272,445 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.12 per share. | 29 Jan 2022 | 41,334 | 2,355,089 (8%) | 0% | 1.1 | 46,294 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.24 per share. | 29 Jan 2022 | 40,834 | 2,280,961 (8%) | 0% | 2.2 | 91,468 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.26 per share. | 29 Jan 2022 | 23,414 | 2,331,675 (8%) | 0% | 1.3 | 29,502 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.66 per share. | 29 Jan 2022 | 22,150 | 2,258,811 (8%) | 0% | 2.7 | 58,919 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.11 per share. | 29 Jan 2022 | 15,692 | 2,403,920 (8%) | 0% | 2.1 | 33,110 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.24 per share. | 29 Jan 2022 | 9,880 | 2,321,795 (8%) | 0% | 1.2 | 12,251 | Common Stock |
| Xeris Biopharma Holdings Inc | John P. Shannon | Director, See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.11 per share. | 29 Jan 2022 | 7,497 | 2,396,423 (8%) | 0% | 2.1 | 15,819 | Common Stock |